Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 814 participants.

Also called NCT02229227

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 814 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02229227
  • EudraCT 2014-001821-34
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Canada, France, Germany, Hungary, Italy, Mexico, Philippines, Poland, South Africa, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02229227. Randomized; no masking; primary purpose treatment. Start 2014-11-21 (actual); primary completion 2017-07-24 (actual). Results posted on 2018-06-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Albiglutide
Intervention (Drug)
Insulin Glargine and Insulin Lispro
Lead sponsor
GlaxoSmithKline (class: industry)
Collaborator
PPD Development, LP (class: industry)

Record details

Record id
cardio:ct-nct02229227
Content hash
ce5f882cf03b7be5451187914ab17528c76c0d8c4a6bab3a3917118ae79c9eea